Feb 27, 2014
NDA meetings with the FDA will commence in the spring 2014, which will allow Acadia to outline the NDA submission and its organization. In regards to registration in the EU, there has been an initial series of interactions with the regulatory agencies from several EU member states. These meetings will continue so as to clarify the pathway for registration in the EU.
Fly On The Wall
March 13, 2014
10:19 EDT PLUG Plug Power says looking for partners in China Plug Power CEO Andy Marsh says the company hopes to have news "soon" on its effort to partner in China. Marsh is speaking on the company's Q4 earnings conference call.
March 12, 2014, 10:39 A.M. ET
Tesla Motors: No New Jersey, No Problem
ACADIA Pharmaceuticals Director Bros. Advisors Lp Baker Acquires 526,316 Shares (ACAD)
Posted by Zach Kirkland on Mar 11th, 2014
ACADIA Pharmaceuticals (NASDAQ:ACAD) Director Bros. Advisors Lp Baker purchased 526,316 shares of the stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average price of $28.50 per share, for a total transaction of $15,000,006.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
ACAD has been the subject of a number of recent research reports. Analysts at Jefferies Group raised their
price target on shares of ACADIA Pharmaceuticals from $26.00 to $38.00 in a research note on Tuesday, March 4th.
Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year
Hep C product on target to unseat Lipitor as the biggest-selling drug ever
March 7, 2014 | By Carly Helfand
With a revolutionary approach to hepatitis C and a price tag of $84,000 per 12-week treatment course, analysts expected big sales from Gilead's ($GILD) Sovaldi. Some even forecast it would reach $9 billion or more by 2017, at which level it would surpass Pfizer's ($PFE) Lipitor to take the crown for biggest-selling drug of all time. But none expected the exponential growth the drug is posting right now.
New Sovaldi prescriptions were up 20% week-over-week for the week ended Feb. 28--the 12th week of Gilead's launch. And according to ISI Group analyst Mark Schoenebaum, that has current projections looking rather slim.
"If prescriptions were to NEVER GROW AGAIN (i.e. flat-line from here), I estimate that 2014 sales will be $8B. If scrips grow an average of 1.5% week over week, I estimate that 2014 sales will be about $11B.
And as RBC analyst Michael Yee notes, Sovaldi's weekly total prescriptions are tracking 114% higher than what Incivek--a Vertex ($VRTX) hep C drug that holds the title for fastest drug launch ever after raking in $1.56 billion in four quarters--did in its first full quarter of launch.
so true, i agree.
Stocks To Watch
Arrowhead Research: ‘Early Innings’ for ‘Major Story’
News and commentary about the stocks you need to know about today
March 5, 2014, 11:50 A.M. ET
By Ben Levisohn
Adam Feuerstein @adamfeuerstein 6h
$ARWR DB picks up coverage with a buy. Yesterday it was RBC. This willl be a $100 stock in 2 months.
do the opposite of holly- known on stocktwits to do the opposite